Canaccord Genuity analyst Max Masucci maintained a Buy rating on GenMark (GNMK) yesterday and set a price target of $12.00. The company’s shares closed last Thursday at $10.25.
According to TipRanks.com, Masucci is a 5-star analyst with an average return of 44.5% and a 56.5% success rate. Masucci covers the Healthcare sector, focusing on stocks such as Chembio Diagnostics, Castle Biosciences, and Guardant Health.
Currently, the analyst consensus on GenMark is a Strong Buy with an average price target of $10.75, representing a 19.6% upside. In a report issued on April 7, Needham also reiterated a Buy rating on the stock with a $11.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.36 and a one-year low of $3.36. Currently, GenMark has an average volume of 2.44M.
Based on the recent corporate insider activity of 119 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GNMK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the provision of multiplex molecular diagnostic solutions. Its products include ePlex and XT-8. The company was founded by Jon Faiz Kayyemin 1993 and is headquartered in Carlsbad, CA.
Read More on GNMK:
